AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01910740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
Study NCT01910740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social Interaction
Description: To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
Study NCT02754752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture Therapy
Description: Undergo electroacupuncture therapy
Study NCT02754752 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Electroacupuncture Therapy
Description: Undergo modified electroacupuncture therapy
Study NCT01469130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
Study NCT02754752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02754752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02754752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02754752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02754752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02754752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02754752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02754752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02754752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02274051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kinetin
Description: Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
Study NCT00645320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
Study NCT02683213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine 20mg once daily for 6 months.
Study NCT02683213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study NCT00911183 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT00911183 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously
Study NCT00911183 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00911183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00911183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposome-encapsulated doxorubicin citrate
Description: Given IV
Study NCT00911183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT00911183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00741689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
Study NCT03985228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified milk
Description: Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.
Study NCT03985228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo milk
Description: Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a.
Study NCT01075100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: 20 mg/m2 on Days 1 and 8
Study NCT01075100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=2.5 on Days 1 and 8
Study NCT05071378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Family, Our Voices
Description: Many Men, Many Voices (3MV) is a seven-session, group-level intervention developed to prevent HIV and sexually transmitted diseases (STDs) among black men who have sex with men (MSM) who may or may not identify themselves as gay. The intervention addresses factors that influence the behavior of black MSM: cultural, social, and religious norms; interactions between HIV and other STDs; sexual relationship dynamics; and the social influences that racism and homophobia have on HIV risk behaviors. Our Family, Our Voices seeks to create an adaptation of Many Men, Many Voices specifically tailored to young people who are members of the house ball community by incorporating elements of family support and resilience afforded to participants in the intervention.
Study NCT01088347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mapatumumab
Description: Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
Study NCT01088347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
Study NCT01088347 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
Study NCT01289197 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Family Check Up
Description: Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
Study NCT03258099 — intervention group
Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study NCT02867332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
Study NCT02867332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Study NCT02867332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Study NCT02867332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
Study NCT02867332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
Study NCT02642159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Study NCT02642159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins
Description: Statins at stable dose without other LMT as clinically indicated.
Study NCT02642159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Description: Statins at stable dose without other LMT as clinically indicated.
Study NCT02642159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02642159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02642159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02642159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02642159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic Drug
Description: Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
Study NCT02642159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihyperglycemic Drug
Description: Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
Study NCT04696926 — intervention group
Intervention type: OTHER
Intervention: Edwards Intuity TM Valve implantation
Description: aortic valve replacement with an Edwards Intuity TM bioprosthesis
Study NCT00512395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural analgesia (Duracain/Fentanyl/Naropin)
Description: naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
Study NCT02339831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAMOPED
Description: Camoped given after surgery
Study NCT02339831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPM passive motion device
Description: passive motion device given after surgery
Study NCT02048228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: genotyping guided therapy Ticagrelor, Clopidogrel
Description: CYP2C19\*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
Study NCT02048228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy clopidogrel
Description: All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
Study NCT01934049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip arthroplasty
Description: Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
Study NCT01934049 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: hip arthroplasty
Description: Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
Study NCT01934049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total Intravenous Anesthesia and Peripheral nerve blocks
Description: Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
Study NCT01283412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
Study NCT01283412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.1\~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
Study NCT01274091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUFA-diet
Description: Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
Study NCT01274091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFA-diet
Description: Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
Study NCT01952626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: intravenous injection
Study NCT01952626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: intravenous injection
Study NCT00707031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00707031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT00707031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
Study NCT00707031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefilled pen injector
Study NCT01934049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Total Intravenous Anesthesia and Peripheral nerve blocks
Description: Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
Study NCT04000425 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: AVENIO ctDNA surveillance kit
Description: AVENIO circulating tumor DNA (ctDNA) Analysis Kits is a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit.
Study NCT00707031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study NCT00707031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study NCT01156961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 10 mg/kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
Study NCT04360733 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis
Study NCT02627014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home physical therapy
Description: once a day: 15 minutes
Study NCT02627014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy in cervical region
Description: 6 treatments: 2 treatments for week~1 treatment = 30 minutes
Study NCT02627014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home physical therapy in cervical region
Description: once a day: 15 minutes
Study NCT04556110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril tert-Butylamine tablets （ Produced by Haisco）
Description: The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
Study NCT04556110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril tert-Butylamine tablets（ACERTIL®）
Description: The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
Study NCT00979160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
Study NCT05517512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Estimation of Protein 13
Description: Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000)~1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20).~2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21).~3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22).
Study NCT05720481 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full mouth Scaling and root planing
Description: patients were treated with full mouth Scaling and root planing
Study NCT05720481 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quadrant Scaling and root planing
Description: patients were treated with quadrant Scaling and root planing
Study NCT00606684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444 6.25
Description: GW642444 6.25
Study NCT00606684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444 3mcg
Description: once daily
Study NCT00606684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444 12.5mcg
Description: GW642444 12.5mcg
Study NCT00606684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444 25mcg
Description: GW642444 25mcg
Study NCT00606684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444 50mcg
Description: GW642444 50mcg
Study NCT00606684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03979209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Mometasone Rinse
Description: Nasal irrigation twice a day (BID) of assigned dose.
Study NCT01465776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01465776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preventative dietary intervention
Description: lyophilized black raspberries(LBR) administration: 3 LBR troche lozenges (dissolved in mouth), 4 times/day beginning at minimum of 24 hrs following biopsy until night before surgery